Format

Send to

Choose Destination
Nanoscale. 2020 Feb 27;12(8):4988-5002. doi: 10.1039/c9nr10620k.

PLGA protein nanocarriers with tailor-made fluorescence/MRI/PET imaging modalities.

Author information

1
Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), 08193 Bellaterra, Catalonia, Spain. anna.roig@csic.es.
2
Neurovascular Research Laboratory, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Catalonia, Spain. anna.rosell@vhir.org.
3
Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 San Sebastian, Guipúzcoa, Spain.
4
University of Artois, Blood-Brain Barrier Laboratory (BBB Lab), UR2465, F-62300 Lens, France.
5
Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 San Sebastian, Guipúzcoa, Spain and CIBERES, Centro de Investigación Biomédica en Red, 28029 Madrid, Spain.
6
Magnetic Resonance Imaging Laboratory, CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 San Sebastian, Guipúzcoa, Spain and Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain.
7
Cardiovascular Diseases Research Group, Vall d'Hebron University Hospital and Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Abstract

Designing theranostic nanocarriers with high protein payload and multimodality tracking without cross interferences between the different imaging probes and the delicate protein cargo is challenging. Here, chemical modifications of poly(lactic-co-glycolic acid) (PLGA) to produce nanocapsules (NCs) that incorporate several imaging moieties are reported. The biocompatible and biodegradable PLGA-NCs can be endowed with a magnetic resonance imaging (MRI) reporter, two fluorescence imaging probes (blue/NIR) and a positron emission tomography (PET) reporter. The modular integration of these imaging moieties into the shell of the NCs is successfully achieved without affecting the morphochemical properties of the nanocarrier or the protein loading capacity. In vivo biodistribution of the NCs is monitored by MRI, PET and NIRF and the results from different techniques are analyzed comparatively. The viabilities of two different human endothelial cells in vitro show no toxicity for NC concentration up to 100 μg mL-1. The morbidity of mice for 2 weeks after systemic administration and the hepatic/pancreatic enzymes at the plasma level indicate their in vivo biosafety. In summary, the new theranostic PLGA nanoplatform presented here shows versatile in vitro/in vivo multimodal imaging capabilities, excellent biosafety and over 1 wt% protein loading.

PMID:
32057060
DOI:
10.1039/c9nr10620k

Supplemental Content

Full text links

Icon for Royal Society of Chemistry
Loading ...
Support Center